Press Release // June 10, 2026   Formycon AG Reports Results of Annual General Meeting 2026   Management Board provides detailed review of fiscal year 2025 and outlook for 2026 Shareholders approve all agenda items by large majorities and formally approve the actions of the Management and Supervisory Boards   Planegg-Martinsried – Formycon AG ( [ … ]

Press Release // May 28, 2026   Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026 Successful start to the year with significant progress across the biosimilar portfolio EU launch of FYB203 expands commercial portfolio to three in-house developed biosimilars FYB206 reaches clinical milestone a [ … ]

Press Release // May 19, 2026  Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive® and Baiama® are now available in the European Union FYB203 (aflibercept) is now available as prefilled syringe under the brand names Ahzantive® and Baiama® in the European Union Phased rollout through multiple commercialization partners in k [ … ]

Press Release // April 22, 2026 Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships Operational milestones achieved across development pipeline and further progress in expanding global market access  “FYB4Growth” strategy combines four strategic pillars into a sc [ … ]

Press Release // April 20, 2026 Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026 Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its results of the financial year 2025 on Apr [ … ]

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014 Formycon AG announces improved preliminary figures for the 2025 fiscal year and sets date for the publication of the annual financial statements Group EBITDA of approx. € -4 million (vs. € -12 million) and adjusted EBITDA of approx. € -2 million (vs. € -7 milli [ … ]